Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2016. (more…)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, announces a trading update.
(more…)
TR-1: Notification of major interest in shares. (more…)
Bioventix plc (AIM: BVXP) announces that it has today applied for 47,725 ordinary shares of 5 pence each (the “Option Shares”) to be admitted to trading on AIM (“Admission”). It is expected that Admission will occur and that dealings will commence in the Option Shares on 18 July 2016. (more…)
TR-1: Notification of major interest in shares. (more…)
Pre Diagnostics and Bioventix enter collaboration on blood-based beta amyloid Alzheimer’s diagnostic test. (more…)
TR-1: Notification of major interest in shares. (more…)
Unaudited interim results for the six months ended 31st December 2015. (more…)
Companies to jointly develop “missing link” Secretoneurin biomarker. (more…)